RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Douglas Miehm has reiterated an 'Outperform' rating on Oncolytics Biotech (TSX:ONC) and maintained a C$6 price target.
August 15, 2023 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an 'Outperform' rating on Oncolytics Biotech and maintained a C$6 price target.
The reiteration of an 'Outperform' rating by RBC Capital indicates a positive outlook for Oncolytics Biotech. The maintained price target of C$6 also suggests that the analyst believes the stock is undervalued, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100